Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Olivier Antoine M. Charmeil

CEOOlivier Antoine M. Charmeil

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

108.11B

Market cap108.11B

Price-Earnings ratio

18.85

Price-Earnings ratio18.85

Dividend yield

3.53%

Dividend yield3.53%

Average volume

4.38M

Average volume4.38M

High today

$45.45

High today$45.45

Low today

$44.71

Low today$44.71

Open price

$45.28

Open price$45.28

Volume

2.78M

Volume2.78M

52 Week high

$58.16

52 Week high$58.16

52 Week low

$43.32

52 Week low$43.32

SNY News

TipRanks 13m

Sanofi Advances Early Autoimmune Antibody Program With New Phase 1 Study Update

Sanofi SA (SNY) announced an update on their ongoing clinical study. Sanofi (SNY) is running a Phase 1 basket study called “A Phase 1, Open-label, Multiple Asc...

Seeking Alpha 46m

AstraZeneca, Sanofi expand R&D footprint in China

AstraZeneca (AZN) and Sanofi (SNY) have become the latest drugmakers in the West to expand R&D operations in China, a market with highly sought-after R&D prospe...

TipRanks 1d

Sanofi’s Amlitelimab Eczema Trial Reaches Completion, Setting Up a Key Pipeline Catalyst

Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi’s latest update covers COAST 2, a Phase 3 trial testing amlitelimab in people 12 and...

Analyst ratings

67%

of 6 ratings

Buy

66.7%

Hold

33.3%

Sell

More SNY News

TipRanks 1d

Sanofi initiated with an Outperform at Bernstein

Bernstein analyst Justin Smith initiated coverage of Sanofi (SNY) with an Outperform rating and EUR 110 price target The firm sees the company’s new CEO unlocki...

Seeking Alpha 2d

Sanofi’s venglustat granted U.S. breakthrough therapy status for type 3 Gaucher disease

The U.S. Food and Drug Administration has granted breakthrough therapy designation to Sanofi’s (SNY) venglustat, a novel, investigational oral glucosylceramide...

TipRanks 3d

Sanofi’s Lunsekimig Asthma Study Completion: What Investors Should Watch Next

Sanofi (SNYNF) announced an update on their ongoing clinical study. The Phase 2b study titled “A Randomized, Double-blind, Placebo-controlled, Parallel-group,...

TipRanks 4d

Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease

Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. The study “A Double-blinded Extension Study to Evaluate...

TipRanks 6d

Sanofi India Flags Transfer of Dormant Shareholdings to IEPF

Sanofi India Limited ( (IN:SANOFI) ) has provided an announcement. Sanofi India Limited has notified stock exchanges that it has published newspaper advertisem...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.